ALSO NOTED: Albany Molecular buys ComGenex; Iomai cuts IPO price; and much more...

> Albany Molecular Research has signed a deal for the stock purchase of Budapest-based ComGenex. Report

> Iomai has cut its IPO to 5 million shares at a price of $7 to $9 each. Release

> Rebel investors in SkyePharma are calling for a special general meeting to force Ian Gowrie-Smith's departure from the board. Gowrie-Smith resigned as chairman a week ago. Report

> The FDA has approved a new indication for Ista's Xibrom eye treatment. Release

> Rigel has received a milestone payment from Merck for their work on ubiquitine ligases. Release

> San Diego-based Stressgen has reorganized with more than $9 million in new funding. Release

> Affymax of Palo Alto, CA, has initiated a Phase II trial of Hematide to treat anemia in cancer patients. Release

> Bayer is licensing two tests from Abbott. Release

> IDM Pharma has released results for its Phase I trial of Collidem Dendritic Cell Vaccine. Release

And Finally... Bill Gates is adding $600 million to his war chest for eradicating TB by 2015. Article